NO20044531L - Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom - Google Patents

Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom

Info

Publication number
NO20044531L
NO20044531L NO20044531A NO20044531A NO20044531L NO 20044531 L NO20044531 L NO 20044531L NO 20044531 A NO20044531 A NO 20044531A NO 20044531 A NO20044531 A NO 20044531A NO 20044531 L NO20044531 L NO 20044531L
Authority
NO
Norway
Prior art keywords
compounds
medicaments
aralkylsulfonamides
imidazolinylmethyl
compositions
Prior art date
Application number
NO20044531A
Other languages
English (en)
Norwegian (no)
Inventor
Counde O'yang
Michael Patrick Dillon
Clara Jeou Jen Lin
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20044531L publication Critical patent/NO20044531L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20044531A 2002-04-23 2004-10-21 Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom NO20044531L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37470002P 2002-04-23 2002-04-23
US37877502P 2002-05-08 2002-05-08
PCT/EP2003/003904 WO2003091236A1 (en) 2002-04-23 2003-04-15 Imidazolinylmethyl aralkylsulfonamides

Publications (1)

Publication Number Publication Date
NO20044531L true NO20044531L (no) 2004-11-19

Family

ID=29273005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044531A NO20044531L (no) 2002-04-23 2004-10-21 Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom

Country Status (22)

Country Link
US (2) US6756395B2 (pl)
EP (1) EP1501817A1 (pl)
JP (1) JP4362379B2 (pl)
KR (1) KR100696561B1 (pl)
CN (1) CN1296365C (pl)
AR (1) AR039319A1 (pl)
AU (1) AU2003227623B2 (pl)
BR (1) BR0309668A (pl)
CA (1) CA2483345C (pl)
HR (1) HRP20040951A2 (pl)
IL (1) IL164676A0 (pl)
MX (1) MXPA04010315A (pl)
MY (1) MY139228A (pl)
NO (1) NO20044531L (pl)
NZ (1) NZ535823A (pl)
PA (1) PA8571401A1 (pl)
PE (1) PE20040172A1 (pl)
PL (1) PL373322A1 (pl)
RU (1) RU2318814C2 (pl)
TW (1) TW200306807A (pl)
UY (1) UY27770A1 (pl)
WO (1) WO2003091236A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501817A1 (en) * 2002-04-23 2005-02-02 F. Hoffmann-La Roche Ag Imidazolinylmethyl aralkylsulfonamides
JPWO2005063678A1 (ja) * 2003-12-26 2007-12-20 第一三共株式会社 フェニル酢酸誘導体の製造方法
MX2010007967A (es) * 2008-02-04 2010-08-09 Hoffmann La Roche N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.
MX2010007929A (es) * 2008-02-04 2010-08-09 Hoffmann La Roche Imidazolinilmetil aril sulfonamidas novedosas.
EP2238114A1 (en) * 2008-02-04 2010-10-13 F. Hoffmann-La Roche AG Novel imidazolinylmethyl aryl sulfonamides
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
CA2711724A1 (en) * 2008-02-04 2009-08-13 F. Hoffmann-La Roche Ag Novel imidazolinylmethyl aryl sulfonamides
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
CN103853429B (zh) * 2014-03-14 2018-01-23 联想(北京)有限公司 信息处理方法、信息处理装置及电子设备
CN105693524A (zh) * 2014-11-28 2016-06-22 浙江省化工研究院有限公司 一种硝基化合物的制备方法
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
KR20230058066A (ko) * 2020-08-27 2023-05-02 큐라센 테라퓨틱스, 인코포레이티드 α1A-아드레날린성 수용체 작용제 및 사용 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
AU3115471A (en) 1970-07-22 1973-01-18 Merck & Co Inc Chemical processes and products
BR9509024A (pt) * 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
TW405272B (en) 1997-06-25 2000-09-11 Sony Corp Method and apparatus for growth of a nitride III-V compound semiconductor
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
US6602897B2 (en) * 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
US20020169193A1 (en) * 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
EP1501817A1 (en) * 2002-04-23 2005-02-02 F. Hoffmann-La Roche Ag Imidazolinylmethyl aralkylsulfonamides

Also Published As

Publication number Publication date
MY139228A (en) 2009-08-28
TW200306807A (en) 2003-12-01
RU2004134326A (ru) 2006-01-27
IL164676A0 (en) 2005-12-18
CN1646516A (zh) 2005-07-27
US20040214875A1 (en) 2004-10-28
CA2483345A1 (en) 2003-11-06
AR039319A1 (es) 2005-02-16
UY27770A1 (es) 2003-10-31
US20030229130A1 (en) 2003-12-11
HK1080463A1 (en) 2006-04-28
RU2318814C2 (ru) 2008-03-10
PE20040172A1 (es) 2004-04-08
HRP20040951A2 (hr) 2006-06-30
MXPA04010315A (es) 2005-06-08
PL373322A1 (pl) 2005-08-22
US6756395B2 (en) 2004-06-29
CA2483345C (en) 2010-12-21
JP4362379B2 (ja) 2009-11-11
CN1296365C (zh) 2007-01-24
NZ535823A (en) 2007-07-27
KR20040102151A (ko) 2004-12-03
EP1501817A1 (en) 2005-02-02
AU2003227623A1 (en) 2003-11-10
US7407980B2 (en) 2008-08-05
KR100696561B1 (ko) 2007-03-19
BR0309668A (pt) 2005-03-01
PA8571401A1 (es) 2004-02-07
JP2005534628A (ja) 2005-11-17
AU2003227623B2 (en) 2010-05-20
WO2003091236A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
GB0022438D0 (en) Organic Compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TW200637828A (en) Novel cis-imidazolines
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TW200716618A (en) Chemical compounds
NO20070570L (no) Forbindelser.
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
GB0428250D0 (en) Organic compounds
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2006074924A8 (en) 3,4,(5)-substituted tetrahvdropyridines
GB0012795D0 (en) Organic compounds
TW200510354A (en) Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application